# bioAffinity Technologies

bioAffinity Technologies is an Asset Manager based in San Antonio, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Antonio, United States
- **Region:** North America
- **Address:** 3300 Nacogdoches Road, Suite 216, San Antonio, TX 78217, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** bioaffinitytech.com
- **LinkedIn:** https://www.linkedin.com/company/bioaffinitytechnologies

## Regulatory record

- **Reports private funds:** No

## About

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- Science Research Laboratories, The University of Texas at San Antonio, San Antonio, TX

## People

- Maria Zannes — President & CEO

## Questions

### What does bioAffinity Technologies actually do?

The company developed and sells CyPath Lung, a noninvasive diagnostic test that uses flow cytometry and AI on sputum samples to detect lung cancer at early stages. The test is processed at Precision Pathology Laboratory Services, a wholly owned, CLIA-certified subsidiary in San Antonio. In a 2023 Respiratory Research publication, CyPath Lung demonstrated 92% sensitivity in high-risk patients.

### Who runs investment and operational decisions at bioAffinity Technologies?

Maria Zannes serves as President and CEO, leading the company since its 2014 founding. The firm has not publicly disclosed a separate chief investment officer or capital allocation committee. Public shareholders set broad corporate direction following the firm's 2022 IPO.

### Does bioAffinity Technologies participate in fund commitments or make external investments?

There is no public evidence that bioAffinity Technologies operates an investment fund, makes fund commitments, or conducts direct venture deals. The company functions as an operating entity commercializing its own diagnostic technology, with capital deployed internally toward R&D, clinical trials, and sales.

### What are CyPath Lung's known performance metrics?

A 2023 trial published in Respiratory Research reported 92% sensitivity and 87% specificity in high-risk patients with pulmonary nodules under 20 millimeters. The test also demonstrated 95% Area Under the Curve with a 99% Negative Predictive Value, making it effective for ruling out cancer and reducing unnecessary biopsies.

## Related profiles

- [Staubli](https://altss.com/profile/staubli)
- [Bird Rides](https://altss.com/profile/bird-rides)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/bioaffinity-technologies

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology